Independent study: significant time saving with Molteno3® GDDs compared to Baerveldt® Devices - 23rd May 2019

Dr Sheybani, lead researcher in study comparing Molteno3® and Baerveldt® devices

Ophthalmologists from Missouri, USA, updated the results from their comparison of Molteno3 and Baerveldt glaucoma implant surgery at the recent AGS Annual Meeting [1,2].  The independent study is ongoing and now includes 113 cases. Key findings were:
1.      Surgical time was more than 11 minutes shorter in the Molteno3 group [1]
2.      IOP, vision change and medication use were equivalent after surgery, despite the smaller area of Molteno3 implants.

In a subsequent interview by Dr Davinder Grover, lead investigator, Dr Arsham Sheybani, added that
1.    patient comfort is better during Molteno3 surgery
2.    Molteno3 implantation requires less manipulation of the extra-ocular muscles
3.    the more pliable Molteno3 tubes require only one relieving slit (compared to two slits in the Baerveldt tube) and
4.    Molteno3 surgical time was shorter despite residents and fellows (trainees and less experienced ophthalmologists) performing many of the surgeries.

This is the first reported study comparing surgical time between Molteno3 and Baerveldt devices. Shorter surgical time is better for the patient, saves surgeon time and significantly reduces costs: one more reason to choose the advanced Molteno3 glaucoma drainage devices for patients with severe or complex glaucoma. 
 

References:
1. Maxwell W. Dixon, Joel Palko, Arsham Sheybani; Comparing the Baerveldt and Molteno Shunts for Treatment of Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2076.  
2. Maxwell W. Dixon, Mathew S. Margolis, Joel Palko, Arsham Sheybani; Differences in Intraocular Pressure and Medication Usage between the Baerveldt and Molteno Glaucoma Drainage Devices. Poster presented at the  American Glaucoma Society 2019 Annual Meeting.

World Glaucoma Week 2019 - 12th Mar 2019

World Glaucoma Week 2019 Early detection of glaucoma saves sight! World Glaucoma Week is a gentle reminder to have your eyes checked regularly. Guidelines suggest an eye check every 5 years from the age of 45. Start eye checks at a younger age if there is a family history or other risk factors such as steroid treatment. 

You may not know you have glaucoma as many types of glaucoma cause few symptoms. People are adaptable and the gradual loss of peripheral vision may not be noticed. Early detection and treatment can prevent losing vision to glaucoma.

Having a relative with glaucoma increases your chances of having glaucoma yourself. Remind family members to have an eye check. An eye check to detect glaucoma generally includes:

  • a test of the visual fields
  • measurement of intra-ocular pressures
  • an examination of the optic discs.
Don't delay, book an eye check today!

World Glaucoma Week is a joint initiative between the World Glaucoma Association and the World Glaucoma Patient Association.

Molteno Ophthalmic takes a summer vacation - 11th Dec 2018

Molteno Ophthalmic takes a summer vacation MOLTENO Ophthalmic has had a busy year. Highlights of 2018 include:

  • exhibiting at major international glaucoma congresses in America, Asia and Europe,
  • participating in large international tenders,
  • a new distributor portal and enhanced distributor support.
  • exciting developments in our R&D projects.
The manufacturing and management teams are taking a summer break to rest and refresh themselves for 2019. 

Customers are encouraged to check stock levels and place orders for Molteno and Molteno3 Glaucoma Drainage Devices by 16th December 2018. 

We wish you a very Merry Christmas and a Happy New Year!

 

Did you know? Historical facts about glaucoma surgery #1: - 11th Oct 2018

Absorbable suture occluding the tube of a Molteno3 implant

In the 1970s a two-stage surgery was developed to prevent hypotony [1]. In the first surgery the plate of the implant was sutured onto the globe beneath Tenon’s tissue, then, in a second surgery 8 weeks later, the tube of the implant was inserted into the anterior chamber (AC). Between the first and second surgeries a thin layer of collagen was laid down in the wall of the bleb (the tissues around the plate) [2]. When the aqueous started draining from the AC, up the tube and into the bleb, the thin layer of collagen prevented hypotony by acting as a flexible barrier.

Unexpectedly, the two-stage surgery also resulted in much less bleb fibrosis and better IOP control. Keeping aqueous out of the bleb for 8 weeks was very beneficial. This technique became known as ‘delayed drainage’.

When Vicryl™(polyglactin) sutures were developed, the two-stage procedure was replaced by a single surgery [3]. At the time of surgery a 5.0 Vicryl suture was tied around the tube, completely blocking all flow. 5.0 Vicryl dissolves after 4-6 weeks so there was a 4-6 week delay before aqueous started to drain into the bleb. This produced similar results to the 8 week two-stage procedure.

Vicryl is a trade mark of Ethicon Inc.

References:
1) Molteno ACB, Van Biljon G, Ancker E: Two-stage insertion of glaucoma drainage implants . Trans Ophthalmol Soc NZ 1979;31:17-26.
2) Molteno AC, Fucik M, Dempster AG, Bevin TH. Otago Glaucoma Surgery Outcome Study: factors controlling capsule fibrosis around Molteno implants with histopathological correlation. Ophthalmology. 2003 Nov 1;110(11):2198-206.
3) Molteno AC, Polkinghorne PJ, Bowbyes JA. The vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma. Australian and New Zealand journal of ophthalmology. 1986 Nov;14(4):343-54.

Molteno Ophthalmic celebrates EN ISO 13485:2016 - 13th Sep 2018

Molteno Ophthalmic staff celebrate meeting the EN ISO 13485:2016 quality standard. Molteno Ophthalmic staff enjoyed a celebratory lunch after a successful audit by DEKRA earlier in the week.
The company's quality management system and implementation meets the requirements of EN ISO 13485:2016, updating our previous EN ISO 13485:2012 certificate.
Particular thanks to Janine Hunter for her hard work as Quality Assurance Manager and to our dedicated staff for their commitment to quality at every step of Molteno and Molteno3 glaucoma drainage device manufacture. 

Molteno3 S-Series glaucoma implants launch in Greece - 16th Jun 2018

The 24th Greek Glaucoma Congress held in Athens was a hive of happy activity as ophthalmologists from Greece and further afield gathered to learn about new developments. Keynote speaker, Prof Mark Sherwood (Florida), an experienced Molteno3 surgeon, addressed the topics ‘Trabeculectomy versus Tube as Primary Procedure’ and ‘New Approaches to Glaucoma Surgery’. Greek surgeons are excited about the Molteno3 S-Series implants, particularly the versatile Molteno3 SS (185mm2) model.  Molteno3 S-Series implants are available from Erghani SA, a specialist ophthalmic distributor.
Erghani SA, in conjunction with Alfa-Intes and MOLTENO Ophthalmic, arranged high-level training in Bologna, Italy for leading glaucoma surgeons so that patients get the best outcomes from Molteno3 surgery. After very positive feedback, further training courses are planned to meet the demand.
Dr Nina Molteno, chief executive at MOLTENO Ophthalmic, travelled to Athens to train the Erghani staff and to meet with the Greek surgeons. She was very impressed by the enthusiasm and dedication of the ophthalmologists, nurses, administrators and the Erghani staff. Those working in government-funded settings are providing ophthalmic services to their patients on extremely tight budgets, yet the clinics were spotless, the staff friendly and the service seemed very efficient. MOLTENO Ophthalmic is proud to be helping such dedicated professionals to save vision and improve the lives of glaucoma patients.  
 

World Glaucoma Week 2018 - 20th Feb 2018

World Glaucoma Week: Eye checks save sight! Molteno Ophthalmic is proudly supporting World Glaucoma Week, March 11-17 2018. Glaucoma is the leading cause of irreversible blindness and currently affects 64 million people worldwide. Glaucoma is a progressive disease that damages the health of the eye, however, blindness is generally preventable if glaucoma is diagnosed and treated early. Many types of glaucoma cause optic nerve damage without the patient being aware of the resulting vision loss until it is advanced.
 
As we work to improve treatment options for those diagnosed with glaucoma, World Glaucoma Week is raising awareness of the importance of getting your eyes tested regularly. The industry standard is to check eye health every two years[1]. Checks for glaucoma are part of a standard eye examination by an optometrist or optician. The tests are not invasive and include a test of intraocular pressure (pressure inside the eye) and assessments of the visual field and optic nerve[2]. You can find out more about these tests by speaking to your optician.
 
Your chances of developing glaucoma significantly increase if you are over forty years old. You are also at much higher risk if you have a close relative with glaucoma.  Having diabetes, high blood pressure, steroid treatment or short sightedness are also risk factors[3]. Get your eyes tested today - it’s not worth risking losing your eyesight!
 
For more information about glaucoma, check out the International Glaucoma Association, the Glaucoma Research Foundation or Glaucoma New Zealand


[1] https://ranzco.edu/media-and-advocacy/blog/fast-facts-about-glaucoma
[2] https://www.specsavers.co.nz/eye-health/eye-conditions/what-is-glaucoma
[3] https://www.glaucoma-association.com/about-glaucoma/should-i-have-an-eye-test

RANZCO Perth 2017 - Competition winner! - 17th Nov 2017

Competition winner, Dr Kheng Sok, with Dr Nina Molteno MOLTENO Ophthalmic had a very successful stand at the recent RANZCO Congress in Perth, Australia, showcasing the advanced Molteno3 S-Series glaucoma implants. 

Ms Emma Carr of RANZCO drew the winner of the MOLTENO Ophthalmic stand competition from a large number of entries. Dr Kheng Sok, an ophthalmologist from Cambodia, was the delighted winner. Dr Sok received a bottle of Quartz Reef Pinot Noir, a premium wine from Central Otago, New Zealand. Congratulations to Dr Sok and thank you to everyone who visited our stand!


 




Molteno® Ophthalmic Limited
PO Box 6322 Dunedin
New Zealand

Phone: +64 3 479 2744
Fax: +64 3 479 2444
Email: sales@molteno.com

site map | privacy statement | About | Contact
 

Subscribe

RECEIVE UPDATES
FROM MOLTENO®

site powered by - Turboweb :: Simple Web Manager